Biomarker and target discovery of type II diabetes in small animal

• Whole blood from C57BL/6 mice – 2uL volume

• 100% specificity and 100% sensitivity on sample classification using Probius signature and biomarker network

• A posteriori analysis of disease pathways involving immune response and glucose and fatty acid metabolism

Cytokine panels in small animals

• Cross-correlation with gold standard immuno-assay in progress

Liver toxicity panels in small animals

• Cross-correlation with kinetic chemistry methods in progress

Screening of tuberculosis and associated co-morbidities

• Human plasma samples from 3 different clinical sites in South Africa

• 90% sensitivity and 90% specificity, exceeding WHO recommendation

• 30 min from sample to information, using simple workflow compatible with patient triaging in underserved communities

• A posteriori repurposing of training data to screen for co-morbidities (HIV)

Specific detection of Insulin analogues in product mixtures

• Mixture samples of Toujeo (insulin-glargine) and Humalog (Insulin-lispro)

• Analogues differing by 3 amino-acid groups and their position

• 100% sensitivity down to 25ag/mL